Sensus Healthcare, Inc. (NASDAQ:SRTS) to Post FY2023 Earnings of ($0.14) Per Share, HC Wainwright Forecasts

Sensus Healthcare, Inc. (NASDAQ:SRTSFree Report) – Investment analysts at HC Wainwright lowered their FY2023 EPS estimates for shares of Sensus Healthcare in a research note issued on Monday, November 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.14) per share for the year, down from their prior forecast of ($0.09). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2023 earnings at $0.08 EPS, Q1 2024 earnings at ($0.03) EPS, Q3 2024 earnings at ($0.01) EPS and FY2024 earnings at $0.04 EPS.

Separately, TheStreet downgraded shares of Sensus Healthcare from a “c” rating to a “d+” rating in a research note on Friday, November 10th.

View Our Latest Stock Analysis on SRTS

Sensus Healthcare Stock Up 1.5 %

Sensus Healthcare stock opened at $2.03 on Wednesday. The company has a market cap of $33.27 million, a PE ratio of -33.83 and a beta of 0.63. Sensus Healthcare has a twelve month low of $1.79 and a twelve month high of $9.62. The company’s 50-day moving average price is $2.47 and its 200-day moving average price is $2.87.

Sensus Healthcare (NASDAQ:SRTSGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $6.04 million. Sensus Healthcare had a negative net margin of 3.58% and a negative return on equity of 1.91%.

Insider Transactions at Sensus Healthcare

In other Sensus Healthcare news, CEO Joseph C. Sardano purchased 10,000 shares of the stock in a transaction dated Thursday, September 14th. The stock was purchased at an average price of $2.88 per share, with a total value of $28,800.00. Following the transaction, the chief executive officer now owns 1,175,293 shares of the company’s stock, valued at $3,384,843.84. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Sensus Healthcare in the first quarter worth $409,000. Dimensional Fund Advisors LP increased its stake in shares of Sensus Healthcare by 92.5% in the first quarter. Dimensional Fund Advisors LP now owns 131,453 shares of the company’s stock worth $1,330,000 after acquiring an additional 63,155 shares during the period. Sei Investments Co. acquired a new stake in shares of Sensus Healthcare in the first quarter worth $216,000. Vanguard Group Inc. increased its stake in shares of Sensus Healthcare by 24.3% in the first quarter. Vanguard Group Inc. now owns 596,224 shares of the company’s stock worth $6,034,000 after acquiring an additional 116,409 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Sensus Healthcare in the first quarter worth $285,000. Hedge funds and other institutional investors own 20.56% of the company’s stock.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

See Also

Earnings History and Estimates for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with's FREE daily email newsletter.